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CLINICAL PRACTICE
 
Clinical Practice
 
This 
 
Journal
 
 feature begins with a case vignette highlighting
a  common  clinical  problem.  Evidence  supporting  various
strategies is then presented, followed by a review of formal
guidelines, when they exist. The article ends with the authors’
clinical recommendations.
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A 72-year-old woman has had an annual Pap-
anicolaou (Pap) smear with normal findings (Fig.
1) for the past 30 years. She finds it difficult to
undergo pelvic examinations because she has
severe arthritis in her hips and vaginal atrophy.
She has not been sexually active since the death
of her husband 10 years earlier, and she wants
to know whether she can stop being screened
for cervical neoplasia.
 
THE CLINICAL PROBLEM
 
Although screening for cervical cancer with the
Pap smear is one of the most effective preventive in-
terventions that clinicians can provide in their offic-
es, concern about the accuracy of the traditional Pap
smear, controversy about the frequency of screening,
and  the  advent  of  new  techniques  raise  questions
about how best to approach screening today. This re-
view considers strategies for optimal cervical-cancer
screening, highlights areas of uncertainty, summariz-
es current guidelines, and provides screening recom-
mendations for the practicing clinician.
 
STRATEGIES AND EVIDENCE
 
Dramatic reductions in the incidence of squamous-
cell cancers of the cervix have accompanied the wide-
spread use of Pap tests in the United States.
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 All U.S.
women who have a cervix and who are or who have
been sexually active — a group that numbers approx-
imately 87 million — are encouraged to participate in
screening programs.
Cervical cancer is thought to be the long-delayed
consequence of sexually transmitted human papillo-
mavirus  (HPV)  infection.
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  In  a  small  minority  of
women exposed to HPV, the infection progresses to
asymptomatic high-grade preinvasive dysplastic lesions
and, ultimately, to invasive cancer. An estimated 40
percent of untreated high-grade lesions will progress
to invasive cancer over an average of 10 years.
 
3
 
 Peri-
odic screening offers many opportunities to discover
and treat preinvasive lesions (Fig. 2). Consequently,
even though HPV infection is common, with screen-
ing a U.S. woman’s lifetime risk of cervical cancer is
estimated to be only 0.8 percent.
 
3
 
Further reductions in the approximately 12,800
cases of cervical cancer that are diagnosed each year
in the United States may be achieved by a variety
of means. Given that about half of the U.S. women
in whom cervical cancer develops have never been
screened,
 
4
 
 efforts aimed at encouraging women to
be screened hold the most promise for reducing the
incidence of and mortality from cervical cancer. Al-
though it is difficult to increase the rate of Pap test-
ing, particularly among women who seldom visit cli-
nicians, practitioners can help by offering screening
to women who are being seen for other reasons. For
example, in one study of a large prepaid health plan
with few barriers to access, most of the women with
invasive cervical cancer had not had a Pap smear in
the three years before their diagnosis, even though
 
Figure 1.
 
 Normal Pap Smear (Papanicolaou Stain, ¬20).
Photomicrograph provided courtesy of Dr. Douglas K. Hanks,
University of California, San Francisco.
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75 percent had been seen in primary care outpatient
clinics during that period.
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Another strategy to reduce the incidence of cancer
is to minimize errors related to the sampling technique
itself and the interpretation of the findings. These er-
rors account for approximately one fourth of all cases
of invasive cervical cancer.
 
6-8
 
 Clinicians can decrease
the likelihood of sampling error — the failure to ob-
tain and transfer dysplastic cells to the slide — by
choosing a method of cell collection that will obtain
adequate samples from the endocervical canal.
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 In a
systematic review of studies that focused on histolog-
ically confirmed high-grade cervical dysplasia,
 
10
 
 the
use of a spatula in combination with an endocervical
brush appeared to increase the rate of detection of
disease without increasing the rate of false positive
findings.
 
AREAS OF UNCERTAINTY
 
Although it is widely accepted that screening for
cervical neoplasia saves lives, there is no consensus
about when screening should start, how long it should
continue, the frequency of screening, or the optimal
screening technique. The information needed to make
informed decisions is, in many respects, incomplete.
 
When to Begin Screening
 
Screening is unlikely to be beneficial before a wom-
an becomes sexually active and thus at risk for expo-
sure to HPV. Concern about the potential inaccuracy
of a woman’s reported sexual history, however, has
prompted recommendations that screening begin at
the age of 18 years, regardless of the woman’s report-
ed sexual activity. Determining the optimal age to be-
gin screening is important for several reasons. Acute
HPV infection is common soon after the initiation
of sexual activity, and most infections clear within 24
months.
 
11,12
 
 These infections can cause cytologic ab-
normalities, the majority of which are not associated
with high-grade cervical dysplasia. These abnormal
findings lead to further diagnostic evaluations.
Treatment of dysplastic lesions with cryotherapy,
the loop electrosurgical excision procedure (known as
LEEP), laser ablation, and cone biopsy is common,
though data are lacking from large-scale studies on
the effect that these interventions may have on future
fertility and pregnancy outcomes. Moreover, false pos-
itive results can cause patients needless anxiety and
concern.
 
13
 
 The transient nature of most HPV infec-
tions, the long preinvasive phase of dysplasia,
 
3
 
 and
the potential harm that can result from overdiagnosis
and overtreatment argue against introducing screen-
ing too soon after the initiation of sexual activity.
Research is needed to quantify the reduction in the
risk of cancer, as well as the harm, that might result
from early initiation of screening.
Many European countries with low rates of cervical
cancer do not screen adolescents and young, sexual-
 
A
 
B
 
C
 
Figure 2.
 
 Abnormal Pap-Smear Findings.
Panel A shows atypical squamous cells of undetermined signif-
icance (Papanicolaou stain, ¬40). Panel B shows a low-grade
squamous intraepithelial lesion (Papanicolaou stain, ¬40). Pan-
el C shows a high-grade squamous intraepithelial lesion (Pap-
anicolaou stain, ¬40). Photomicrographs provided courtesy of
Dr. Douglas K. Hanks, University of California, San Francisco.
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ly active women. For example, the National Health
Service of the United Kingdom recommends that
screening begin at the age of 21 years, and the Finnish
Cancer Organization recommends beginning screen-
ing at the age of 30 years.
 
When to End Screening
 
Although most cases of cervical cancer and deaths
from cervical cancer occur in women older than 50
years of age, most of these women have not been
screened adequately. The very low incidence of new
cases of cervical disease among older women who have
no evidence of recent disease and who have been
screened regularly and properly
 
14-17
 
 argues against
continued screening in this population. Furthermore,
with advancing age or the presence of serious coex-
isting conditions, the potential benefits of screening
are offset by the likelihood that a woman will die of
another cause or will suffer needlessly as a conse-
quence of a false positive result.
 
15
 
 Older women who
have undergone a total hysterectomy for diseases oth-
er than cervical neoplasia are not at risk for cervical
cancer and should not be screened.
 
18
 
 Practitioners
should be aware, however, that some women may have
undergone a supracervical hysterectomy in which the
cervix is retained.
 
Frequency of Screening
 
Repeated screening after a normal result can de-
tect abnormalities missed on earlier tests, as well as
abnormalities that have developed since the first test.
The frequency of screening should therefore depend
on the sensitivity of the screening test and the rate
of progression of preinvasive disease.
 
19
 
 An individual
woman’s risk factors should have little effect on the
frequency of screening unless these factors are asso-
ciated with low test sensitivity (as may be the case if
a woman has had only one prior test with normal re-
sults, which may have missed disease) or an accelerat-
ed rate of progression of preinvasive disease (as may
be the case in an immunocompromised woman).
Although the absolute risk of the development of
invasive squamous-cell cancer as a consequence of a
false negative test is small (occurring in fewer than
5 women per 100,000 per year), annual screening has
been common practice in the United States for many
years. There is little evidence to suggest, however, that
outcomes are substantially better with annual screen-
ing than with biennial
 
20
 
 or triennial
 
21 
 
screening. Al-
though a single conventional Pap test may have a rel-
atively low sensitivity,
 
3
 
 the cumulative sensitivity of
several tests performed within a relatively short time
should be high. No cytologic test, however, is likely
to detect cervical neoplasia in the unknown but small
percentage of women with disease in whom abnormal
cells are not exfoliated.
High-grade dysplasia or rapidly progressive cervical
disease is unlikely to be overlooked or to develop
within three years after a normal examination in im-
munocompetent women who have had multiple nor-
mal smears. Further research is needed to determine
the optimal number of normal results after which the
interval between tests can safely be lengthened. Be-
cause the preinvasive stage of disease may be briefer in
women who are immunocompromised, women who
are receiving immunosuppressive therapy or those who
are infected with the human immunodeficiency virus
(HIV) are thought to be poor candidates for less fre-
quent screening. In the case of women with HIV in-
fection, a pattern of annual testing after two tests per-
formed six months apart have had normal results has
been shown to be cost effective.
 
22
 
Newer Methods of Screening
 
Litigation and media coverage have led to broad
public awareness of the imperfect sensitivity of Pap
smears. Several new techniques are being promoted
that increase sensitivity by reducing errors in sampling
and interpretation. Clinicians should be aware that all
such techniques may also decrease specificity: more
abnormalities may be discovered at the cost of an in-
crease in the number of healthy women who are un-
necessarily alarmed by a false report of an abnormality
and who subsequently undergo needless diagnostic
procedures and interventions.
Among the most commonly used innovations in
cervical-cancer screening is liquid-based cytologic col-
lection and analysis. The literature on this technique,
which has been approved by the Food and Drug Ad-
ministration  for  primary  screening,  is  voluminous,
and three systematic reviews have been published re-
cently.
 
23-25
 
 Two found evidence of improved sensitiv-
ity,
 
23,24
 
 and one found evidence of decreased speci-
ficity.
 
23
 
 All three concluded that too few studies of
sufficient methodologic rigor have been performed
to indicate the true accuracy of liquid-based cytolog-
ic analysis, with the chief concern being inadequate
data on specificity.
Reevaluation of conventional smears initially inter-
preted as negative, either on the basis of a manual re-
view or with the assistance of a computerized tech-
nique, can also improve the sensitivity of testing by
decreasing errors in the interpretation of results. Liq-
uid-based preparations and computerized rescreening
increase both the sensitivity and the costs of screen-
ing for cervical cancer. The cost effectiveness of these
methods depends on the manner in which they are
used. They are most likely to be cost effective if they
are used as an adjunct to a program in which screen-
ing is done every three years; the cost per year of life
saved is very high if they are used to improve the sen-
sitivity of annual screening. 
Liquid-based cytologic collection and analysis and
computerized rescreening are most likely more cost
effective when they are used by laboratories where tests
have relatively poor sensitivity. They are unlikely to
The New England Journal of Medicine 
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be cost effective when they are adopted by laborato-
ries that already interpret Pap smears with a high de-
gree of accuracy.
 
26
 
 Cost-effectiveness models to date
have assumed that the specificity of new techniques
is no different from that of older approaches; if liq-
uid-based cytologic collection and analysis have a low-
er specificity, for example, the cost effectiveness will
be adversely affected.
 
27
 
 
The advent of newer methods of HPV detection
has led to increasing interest in the role of testing for
this virus in screening. One of the most promising
uses of HPV testing is to determine which women
with low-grade cytologic abnormalities require col-
poscopic evaluation. Preliminary results of a random-
ized trial designed to clarify the roles of HPV testing,
repeated Pap testing, and colposcopy in the evalua-
tion of low-grade abnormalities indicate that HPV
testing can help identify which women with a single
smear that shows atypical squamous cells of undeter-
mined significance should undergo colposcopy,
 
28
 
 but
that it is not as helpful in women with smears that
show  low-grade  squamous  intraepithelial  lesions.
 
29
 
Less information is available for other uses of HPV
testing, and important questions remain about the
implications of a positive HPV test. There is little
evidence to support the use of any specific manage-
ment strategy for a woman with no detectable cer-
vical disease who is found to have a high-risk type of
HPV. At present, the role of HPV testing as an ad-
junct to or substitute for established and effective cy-
tologic screening programs has not been evaluated
adequately.
 
30
 
GUIDELINES
 
The American Cancer Society
 
31
 
 and the American
College of Obstetricians and Gynecologists
 
32
 
 recom-
mend that screening begin at the age of 18 years, re-
gardless of whether a woman is sexually active. The
American Academy of Family Physicians, the Canadian
Task Force on Preventive Health Care, the American
College of Preventive Medicine, and the U.S. Preven-
tive Services Task Force support the view that screen-
ing should be initiated when women become sexually
active.
 
33
 
 The latter two recommend beginning screen-
ing at the age of 18 years if a woman’s sexual history
is unknown or if the reported history is thought to
be unreliable.
Most groups do not specify an age at which screen-
ing may end, though the U.S. Preventive Services
Task Force recommends discontinuing screening in
women  over  the  age  of  65  years  who  have  been
screened regularly and who have had consistently nor-
mal results. The Canadian Task Force recommends
that such women should stop being screened at the
age of 69 years. The American College of Preventive
Medicine recommends that screening be stopped at
the age of 65 years in women who have undergone
regular screening and who have had no abnormal re-
sults within the previous nine years. All guidelines
state that the interval between tests may be extended
to as long as three years if two or three consecutive
tests have been normal. Some guidelines, however, in-
dicate that continued annual screening be considered
in women with certain risk factors, such as a first oc-
currence of sexual intercourse at an age of less than 18
years, multiple sexual partners or a consort with mul-
tiple sexual partners, smoking, or low socioeconom-
ic status.
 
CONCLUSIONS AND RECOMMENDATIONS
 
The Pap smear remains the archetype of a success-
ful preventive intervention. Some strategies used to
increase the sensitivity of screening — such as new-
er methods of collection and interpretation, as well
as more frequent testing — may, however, also in-
crease the false positive rate. Clinicians should con-
sider the costs and consequences of false positive tests
along with the benefits that result from heightened
sensitivity.
Women obtain health care information from diverse
sources, including the mainstream press and direct-
to-consumer marketing. They may perceive recom-
mendations for less frequent screening, the policy of
discontinuing screening after a certain age, and the
slow rate of adoption of new screening methods as
attempts to save money at their expense, even when
respected professional groups are the source of the
recommendations. Women who have actively partic-
ipated in screening programs and who have had no
evidence of cervical disease should be informed that
their absolute risk of undiagnosed but clinically im-
portant cervical disease is very small and that any ad-
ditional benefits of frequent screening with conven-
tional smears and more sensitive techniques are likely
to be small. Evidence concerning technological ad-
vances in screening, such as liquid-based cytologic col-
lection and analysis and HPV testing, accrues rapidly
and will need to be continually updated and summa-
rized. In the future, combinations of techniques and
more focused screening strategies hold the promise of
making screening more effective, safer, and less costly.
In summary, practitioners should seek out and of-
fer screening to women at risk for cervical cancer who
have not been screened within at least the preceding
three years. Until better data become available, screen-
ing should begin after the initiation of sexual activity
or the age of 18 years if information about a woman’s
sexual history is unknown or is deemed unreliable.
Regularly screened women who are 65 years of age
or older and who have a documented history of con-
secutive normal Pap smears and no evidence of recent
cervical dysplasia gain little from continued screening,
especially if they are no longer sexually active. This
is the case for the woman described in the clinical
vignette. Women who have undergone a total hys-
terectomy for diseases other than cervical neoplasia
The New England Journal of Medicine 
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should no longer be screened. In the case of immu-
nocompetent women who have had multiple consec-
utive normal Pap smears, clinically important cervical
disease is unlikely to develop within a period of three
years and the interval between tests could probably be
safely extended to as long as three years. Clinicians
should remain up to date about the benefits and harms
associated with various screening strategies so that they
can provide women with accurate and complete infor-
mation to facilitate fully informed decision making.
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